Updated: 12/24/2018

Selective Estrogen Receptor Modulators (SERMs)

0%
Topic
Review Topic
0
0
N/A
N/A
Questions
2 2
0
0
0%
0%
Evidence
2 2
0
0
Tamoxifen
  • Mechanism
    • estrogen antagonist in breast
    • estrogen agonist in endometrium, bone
  • Indications
    • estrogen-receptor positive breast cancer
  • Toxicity
    • ↑ risk of DVTs
    • ↑ risk of endometrial cancer
      • secondary to agonist activity
    • induces menopause
      • hot flashes
    • prevents osteoporosis
      • secondary to agonist action in bone
Raloxifene
  • Mechanism 
    • estrogen antagonist in breast
    • estrogen agonist in bone
  • Indications
    • osteoporosis in menopausal women
  • Toxicity
    • ↑ risk of DVTs
    • induces menopause
      • hot flashes
    • NO ↑ risk of endometrial cancer
      • secondary to antagonist activity in endometrium
 

Please rate topic.

Average 5.0 of 2 Ratings

Questions (2)
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK

(M1.RP.12.106) A 46-year-old female presents with a primary complaint of irregular menstrual bleeding that has persisted for the last several months. Her medical history consists of 2 full-term pregnancies and invasive ductal carcinoma of the breast that was successfully treated one year ago. After an appropriate evaluation, she is given a diagnosis of type 1 endometrioid adenocarcinoma. Which of the following factors most likely increased this patient’s risk for developing this cancer? Tested Concept

QID: 100407
1

Administration of raloxifene in the treatment of her previous breast cancer

8%

(16/205)

2

The patient is 46-years-old and has yet to enter menopause

5%

(10/205)

3

Combined oral contraceptive use from the age of 32 to 42

7%

(15/205)

4

The patient’s two previous pregnancies

4%

(8/205)

5

Tamoxifen regimen used to treat her previous breast cancer

73%

(150/205)

M 4 E

Select Answer to see Preferred Response

Evidence (2)
Topic COMMENTS (7)
Private Note